X CHEM KUTATAS FEJLESZTESI ZARTKORUEN MUKODO RESZVENYTARSASAG

Their core work

X-Chem is a Budapest-based private R&D company specializing in advanced synthetic chemistry, with a focus on continuous flow chemistry and photocatalysis as tools for building new organic molecules. They contribute to multi-partner research consortia by developing and testing chemical processes in flow reactors and photoreactors, exploring both homogeneous and heterogeneous catalytic routes. Their work bridges laboratory-scale mechanistic understanding with practical reactor design — making them useful at the interface of academic chemistry and scalable chemical processes. The company name explicitly includes "research and development," reflecting their identity as a science-driven SME rather than a production house.

What they specialise in

How they've shifted over time

X-Chem entered H2020 funding through FLIX with a focus on isotopic labeling — a niche but high-value area for pharmaceutical research — using flow chemistry and classical catalytic methods as the delivery mechanism. By their second project (PhotoReAct, starting 2021), the isotopic angle dropped entirely and was replaced by photocatalysis, photoreactor design, and reaction methodology development, while flow chemistry remained the constant thread. The shift suggests a deliberate move from isotope-specific applications toward a broader synthetic chemistry platform built around light-driven reactions and continuous-flow hardware.

X-Chem is consolidating around photocatalysis combined with flow reactor technology — a direction aligned with green chemistry and pharmaceutical process intensification trends, making them a candidate partner for consortia targeting sustainable synthesis or drug discovery process development.

How they like to work

X-Chem has participated exclusively as a consortium partner — never as coordinator — across both projects, suggesting they prefer to contribute specialist chemistry expertise within larger academic-led or multi-industry teams rather than managing project administration. With 20 distinct partners across 11 countries from just 2 projects, they operate inside sizeable, internationally diverse consortia typical of MSCA-ITN and RIA frameworks. This points to an organization comfortable working within structured, multi-partner environments where their technical contribution is well-defined.

X-Chem has built a network of 20 unique consortium partners spread across 11 countries through only two projects — an unusually broad reach for a small SME, reflecting the large consortium structures of MSCA-ITN and RIA calls. No geographic concentration is apparent from the data, suggesting they engage with pan-European academic and industrial networks rather than a regional cluster.

What sets them apart

X-Chem occupies an uncommon position as a private R&D SME in synthetic chemistry — not a university, not a large chemical company — giving them the flexibility of a small company with the research depth of an academic partner. Their combination of flow chemistry infrastructure, photocatalytic expertise, and mechanistic insight covers the full chain from reaction design to reactor implementation, which is rare at SME scale. For a consortium needing an industrial-facing chemistry partner who can bridge lab results toward scalable processes without the overhead of a large chemical corporation, X-Chem fits a gap that academic institutions and multinationals both struggle to fill.

Highlights from their portfolio

• FLIX
  The larger of the two projects (EUR 425,000), FLIX targets isotopic exchange via flow chemistry — a specialized pharmaceutical-adjacent application with high commercial value in drug development and tracer production.
• PhotoReAct
  PhotoReAct signals X-Chem's strategic move into photocatalysis and photoreactor technology, positioning them at the intersection of green chemistry and continuous manufacturing — a rapidly growing space in EU-funded research.